Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hodgkin Disease × AFM13 × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 2 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 154 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 80 Etoposide 77 Mycophenolic Acid 74 Whole-Body Irradiation 71 Melphalan 62 fludarabine 59 Tacrolimus 59 Filgrastim 59 Busulfan 58 Radiotherapy 52 Doxorubicin 50 Rituximab 49 Cyclosporine 47 Brentuximab Vedotin 44 Antilymphocyte Serum 40 Vinblastine 38 Granulocyte Colony-Stimulating Factor 37 Gemcitabine 34 Dacarbazine 33 Methotrexate 32 Cytarabine 32 Bleomycin 28 Nivolumab 26 Carmustine 26 Vincristine 24 Sirolimus 24 Prednisone 24 Bendamustine Hydrochloride 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02321592 2020-11-13

GHSG-AFM13

University of Cologne

Phase 2 Completed

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡